JP7048505B2 - Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置 - Google Patents

Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置 Download PDF

Info

Publication number
JP7048505B2
JP7048505B2 JP2018543455A JP2018543455A JP7048505B2 JP 7048505 B2 JP7048505 B2 JP 7048505B2 JP 2018543455 A JP2018543455 A JP 2018543455A JP 2018543455 A JP2018543455 A JP 2018543455A JP 7048505 B2 JP7048505 B2 JP 7048505B2
Authority
JP
Japan
Prior art keywords
pdgf
breast cancer
antibody
estrogen
negative breast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018543455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501957A5 (enExample
JP2019501957A (ja
Inventor
エリクソン，ウルフ
ピエトラス，クリスチアン
ロズワール，ペルニラ
Original Assignee
パラクリン セラピューティクス エービー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パラクリン セラピューティクス エービー filed Critical パラクリン セラピューティクス エービー
Publication of JP2019501957A publication Critical patent/JP2019501957A/ja
Publication of JP2019501957A5 publication Critical patent/JP2019501957A5/ja
Priority to JP2022011194A priority Critical patent/JP2022058781A/ja
Application granted granted Critical
Publication of JP7048505B2 publication Critical patent/JP7048505B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2018543455A 2015-11-10 2016-11-10 Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置 Active JP7048505B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022011194A JP2022058781A (ja) 2015-11-10 2022-01-27 Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1551455-7 2015-11-10
SE1551455 2015-11-10
SE1650974-7 2016-07-04
SE1650974 2016-07-04
PCT/EP2016/077295 WO2017081171A1 (en) 2015-11-10 2016-11-10 Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022011194A Division JP2022058781A (ja) 2015-11-10 2022-01-27 Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置

Publications (3)

Publication Number Publication Date
JP2019501957A JP2019501957A (ja) 2019-01-24
JP2019501957A5 JP2019501957A5 (enExample) 2019-12-19
JP7048505B2 true JP7048505B2 (ja) 2022-04-05

Family

ID=57321296

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018543455A Active JP7048505B2 (ja) 2015-11-10 2016-11-10 Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置
JP2022011194A Pending JP2022058781A (ja) 2015-11-10 2022-01-27 Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022011194A Pending JP2022058781A (ja) 2015-11-10 2022-01-27 Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置

Country Status (6)

Country Link
US (2) US11633382B2 (enExample)
EP (1) EP3373967B9 (enExample)
JP (2) JP7048505B2 (enExample)
CN (1) CN108348605B (enExample)
AU (1) AU2016352592B2 (enExample)
WO (1) WO2017081171A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3666276A1 (en) * 2018-12-14 2020-06-17 dcic Biopharmaceutical Limited Medication against estrogen-receptor beta (erbeta) positive breast tumor
BR112022020322A2 (pt) * 2020-04-10 2022-12-13 Jina Pharmaceuticals Inc Método para gerenciar ou diminuir um risco de efeitos adversos em um paciente submetido ao tratamento de distúrbio bipolar i
US20250306008A1 (en) * 2021-01-29 2025-10-02 Korea Advanced Institute Of Science And Technology Pharmaceutical composition for treating or preventing malignant breast cancer
WO2023172891A2 (en) * 2022-03-07 2023-09-14 Baylor College Of Medicine Biomarkers for combination therapy for er+ breast cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015515487A (ja) 2012-04-24 2015-05-28 スロンボジェニックス エヌ．ブイ． 抗ｐｄｇｆ−ｃ抗体

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2464203A (en) 1943-05-21 1949-03-15 Boots Pure Drug Co Ltd Manufacture of dienoestrol
US2465505A (en) 1944-12-05 1949-03-29 Hoffmann La Roche Process for the manufacture of 3, 4-di-(p-hydroxy-phenyl)-hexadiene-2, 4
US2914562A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Amine derivatives of triphenylethanol
BE637389A (enExample) 1962-09-13
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4230862A (en) 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
DE2658307C2 (de) 1976-12-22 1979-03-15 Klinge Pharma Gmbh & Co, 8000 Muenchen Di-O'-hydroxyphenyD-alkanverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE2860900D1 (en) 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
DE3046719C2 (de) 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US5491173A (en) 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
IE58417B1 (en) 1984-04-27 1993-09-22 Ici Plc Chemical derivatives
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
US5352795A (en) 1986-03-07 1994-10-04 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
EP0260066B1 (en) 1986-09-11 1990-05-09 National Research Development Corporation Tamoxifen derivatives
GB8714013D0 (en) 1987-06-16 1987-07-22 Ici Plc (substituted-aralkyl)heterocyclic compounds
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
AU665690B2 (en) 1992-05-08 1996-01-11 Otsuka Pharmaceutical Factory, Inc. Indole derivative
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
GB9326332D0 (en) 1993-12-23 1994-02-23 Karo Bio Indole derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
DE4426625A1 (de) 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
CZ217298A3 (cs) 1996-01-11 1999-01-13 Novo Nordisk A/S Použití 3,4-difenyl chromanů pro výrobu farm. prostředku
PL328135A1 (en) 1996-01-11 1999-01-18 Novo Nordisk As Application of 1-centchromane enantiomer in production of a pharmaceutic agent for preventing or treating mammary cancers
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US5985910A (en) 1996-04-19 1999-11-16 American Home Products Corporation 3- [4- (2- Phenyl-Indole-1-ylmethyl) Phenyl]- Acrylamides as estrogenic agents
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
ZA982819B (en) 1997-04-09 1999-10-04 Lilly Co Eli Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
ZA982877B (en) 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
ZA982818B (en) 1997-04-09 1999-10-04 Lilly Co Eli Prevention of breast cancer using selective estrogen receptor modulators.
ATE295834T1 (de) 1997-08-07 2005-06-15 Lilly Co Eli 1-(4-substituierte alkoxy)benzylnaphthalinderivate als östrogeninhibitoren
AR015500A1 (es) 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6548491B2 (en) 1997-12-24 2003-04-15 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6069153A (en) 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
JP2002522425A (ja) 1998-08-07 2002-07-23 カイロン コーポレイション エストロゲンレセプターモジュレーターとしての置換イソオキサゾール
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US6340774B1 (en) 2000-01-31 2002-01-22 The Board Of Trustees Of The Leland Stanford Junior University Non-steroidal estrogen-receptor antagonists
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US7041839B2 (en) 2000-06-22 2006-05-09 Northeastern University Steroidal antiestrogens and antiandrogens and uses thereof
US6750213B2 (en) 2000-10-19 2004-06-15 Merck & Co., Inc. Estrogen receptor modulators
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
US6599921B2 (en) 2001-02-22 2003-07-29 Nanodesign, Inc. Non-steroidal estrogen receptor ligands
US6927224B2 (en) 2001-08-11 2005-08-09 Bristol Myers Squibb Company Selective estrogen receptor modulators
WO2003015761A1 (en) 2001-08-13 2003-02-27 Merck & Co., Inc. Selective estrogen receptor modulators
US7138426B2 (en) 2002-04-24 2006-11-21 Merck & Co., Inc. Estrogen receptor modulators
WO2005087812A1 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
AR051597A1 (es) 2004-11-01 2007-01-24 Merck & Co Inc Moduladores de los receptores de estrogeno
AU2007240429A1 (en) 2006-04-17 2007-11-01 Ludwig Institute For Cancer Research Ltd Methods and compositions for modulation of blood-neural barrier
EP2068911A4 (en) * 2006-09-13 2011-08-03 Arca Biopharma Inc METHOD FOR THE TREATMENT OF CANCER
US7504530B2 (en) 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
NZ586125A (en) * 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
EP2558098A2 (en) 2010-04-16 2013-02-20 Novartis AG Treatment of endocrine resistant breast cancer
HK1216502A1 (zh) 2012-11-02 2016-11-18 Repros Therapeutics Inc. 用於癌症治療的反式-克羅米芬

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015515487A (ja) 2012-04-24 2015-05-28 スロンボジェニックス エヌ．ブイ． 抗ｐｄｇｆ−ｃ抗体

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Am. J. Pathol. (2013) vol.182, no.6, p.2037-2047
Br. J. Cancer (2008) vol.99, issue 7, p.1056-1063
Cancer Lett. (2009) vol.275, issue 2, p.178-184
Eur. J. Cancer (2005) vol.41, issue 13, p.1980-1989
Int. J. Mol. Sci. (2014) vol.15, issue 11, p.20306-20320
Int. J. Oncol. (2014) vol.45, issue 5, p.2167-2175
J. Cancer Res. Ther. (2014) vol.10, issue 14, p.1107-1108
J. Cell. Biochem. (1997) vol.67, issue 1, p.55-65
Oncogene (2013) vol.32, no.5, p.554-563

Also Published As

Publication number Publication date
JP2022058781A (ja) 2022-04-12
US20230310385A1 (en) 2023-10-05
US11633382B2 (en) 2023-04-25
CN108348605A (zh) 2018-07-31
US20210186932A1 (en) 2021-06-24
EP3373967C0 (en) 2023-06-07
CN108348605B (zh) 2023-06-09
AU2016352592A1 (en) 2018-04-26
EP3373967B1 (en) 2023-06-07
WO2017081171A1 (en) 2017-05-18
EP3373967A1 (en) 2018-09-19
JP2019501957A (ja) 2019-01-24
EP3373967B9 (en) 2023-10-04
AU2016352592B2 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
JP2022058781A (ja) Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置
Arpino et al. Treatment of human epidermal growth factor receptor 2–overexpressing breast cancer xenografts with multiagent HER-targeted therapy
Huober et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer–results of the eLEcTRA trial
TWI402064B (zh) 癌症治療
JP2023071657A (ja) がんの処置における使用のためのＩＬ－１β結合性抗体
Johnston Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations
ES2877757T3 (es) Tratamiento terapéutico de cáncer de mama basado en el estado de c-MAF
US20190045758A1 (en) Biomarker and Therapeutic Target for Triple Negative Breast Cancer
JP2011513427A (ja) ｃ−ｍｅｔ及びＥＧＦＲアンタゴニストの併用療法
JP2014508782A (ja) ホルモン不応性乳癌の治療におけるｅｇｆｒファミリー受容体の阻害剤の使用
JP6879924B2 (ja) 医薬として使用するための、タスキニモドまたはその薬学的に許容される塩とｐｄ−１および／またはｐｄ−ｌ１阻害剤との組み合わせ剤
JP2015502366A (ja) 薬物療法を改善するための方法
TWI729393B (zh) 抑制scube2，一新穎vegfr2輔受體，遏止腫瘤血管新生
Barnett et al. Endoglin promotes angiogenesis in cell-and animal-based models of retinal neovascularization
UA129351C2 (uk) Кон'югат антитіла до тканинного фактора з лікарським засобом та його застосування для лікування раку
AU2016261770B2 (en) Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same
Su et al. Endocan blockade suppresses experimental ocular neovascularization in mice
US20150147386A1 (en) Egfr antagonist for the treatment of heart disease
JP2022514087A (ja) ＩＬ－１β結合抗体の使用
JP6712226B2 (ja) エキセメスタン及びエベロリムスと組み合わせてインスリン様成長因子（ｉｇｆ）受容体アンタゴニストを用いる癌治療
CN110191897A (zh) 用于预防暴露于诱导p38活化的癌症治疗的受试者的转移的治疗
JP2022044827A (ja) 免疫媒介性がん治療のための組成物及び方法
US20240368259A1 (en) Antibodies against lefty proteins
Paratala Translational relevance of RET gene alterations in breast cancer
Chumsri et al. Endocrine Therapy in the Preoperative Setting and Strategies to Overcome Resistance

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180713

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20191015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191017

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20191017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210629

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220127

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220127

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220207

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220302

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220324

R150 Certificate of patent or registration of utility model

Ref document number: 7048505

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250